AIM ImmunoTech Inc.
AIM ImmunoTech Inc. (AIM) Revenue
Annual & quarterly revenue history · segment & region breakdown
AIM · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAIM ImmunoTech Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 48.24% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -48.24% |
| 2024-12-31 | $0.00B | -$0.00B | -15.84% |
| 2023-12-31 | $0.00B | +$0.00B | +43.26% |
| 2022-12-31 | $0.00B | +$0.00B | +4.44% |
| 2021-12-31 | $0.00B | -$0.00B | -17.18% |
| 2020-12-31 | $0.00B | +$0.00B | +16.43% |
| 2019-12-31 | $0.00B | -$0.00B | -61.85% |
| 2018-12-31 | $0.00B | -$0.00B | -16.02% |
| 2017-12-31 | $0.00B | +$0.00B | +375.00% |
| 2016-12-31 | $0.00B | -$0.00B | -30.83% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income AIM ImmunoTech Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
AIM ImmunoTech Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from AIM ImmunoTech Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AIM revenue · 4 questionsAIM's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 48.24% year-over-year from $0.00B in FY2025.
▸ Source: FMP · AIM ImmunoTech Inc. SEC filings · GAAP · AIM ImmunoTech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026